Company Overview and News
New Delhi: Bharti Airtel Ltd has identified two new areas—healthcare and education—around which it plans to build content apart from sharpening focus on regional music and videos on its platform as it braces for a long battle with rival Reliance Jio Infocomm Ltd. Airtel expects the current round of battle will centre around content as cut-rate data tariffs have ceased to provide a meaningful competitive edge in the hyper-intensive telecom industry.
532454 500325 RELIANCE RIGD BHRQY BHARTIARTL RLNIY
Aircel, which is 74% owned by Maxis Communications Bhd, reportedly owes about 50,000 crores to its creditors. Aircel is among the casualties of the intense competition in the Indian telecom market.
SRLRY 532454 RCOM 532374 PNJZY 532461 PNB STRTECH 532712 BHRQY BHARTIARTL SBAZ
The assets of the beleaguered telecom company Aircel are up for sale and Bharti Airtel, Sterlite Technologies, among others and two investment firms are reportedly keen to separately buy them. Despite the number of interested buyers, the lenders to Aircel may still have to take a large haircut, according to Livemint.
SRLRY 532454 532374 PNJZY 532461 PNB STRTECH BHRQY BHARTIARTL SBAZ
SYDNEY (Sept 20): Bharti Airtel, Reliance Jio, Sterlite Technologies and two investment firms have bid to separately purchase assets of Aircel, the company linked to Malaysian tycoon T. Ananda Krishnan, Mint reports, citing two unidentified people with knowledge on the matter.
SRLRY 532454 532374 STRTECH BHRQY BHARTIARTL
Mumbai/New Delhi: Bharti Airtel Ltd, Reliance Jio Infocomm Ltd, Sterlite Technologies Ltd and two investment firms have bid to separately purchase assets of Aircel Ltd, but lenders to the bankrupt telecom operator may still have to take a large haircut. Lenders to Aircel are, however, keen on a lump sum sale to a single party as it believes such a move would lead to the best outcome, two people with knowledge of the matter said.
STRTECH BHRQY 532712 532775 GTLINFRA SRLRY 532454 PNJZY RCOM 532374 532461 PNB BHARTIARTL SBAZ
Equity benchmarks ended a volatile trading day on a negative note as consumer names as well as banks weighed. The Nifty ended below 11,250-mark, while the Sensex shed a little over 160 points. Rupee heading towards its low points also dented sentiment on the market.
524715 500325 INDUSINDBK RELIANCE 532978 BHRQY 533278 532454 BAJAJFINSV 532187 RIGD SUNPHARMA BHARTIARTL CLNDY COALINDIA RLNIY
Mumbai: The BSE Sensex rebounded over 100 points in opening trade Wednesday on value-buying in recently battered stocks amid strength in the rupee and positive global cues. The 30-share BSE index recovered by 142.26 points, or 0.38 per cent, to 37,432.93 in opening trade. The index had lost almost 800 points in the previous two sessions as rupee woes and trade war worries spooked investors. The NSE Nifty was up 50.
BAJAJ-AUTO 532977 BHRQY 533278 532215 500470 532187 AXISBANK 500570 BHARTIARTL TATAMOTORS CLNDY AXB INDUSINDBK IBN AXBKY 532454 AXBA ICICIBANK TTST TATASTEEL TATLY 532174 COALINDIA TTM
The world’s largest professional network, LinkedIn, on Tuesday announced the 2018 LinkedIn Top Startups List for India, revealing the 25 most-wanted startups by professionals.
BRK.A 532454 DB 500477 BHRQY BHARTIARTL AKLS AKLD ASHOKLEY
Mumbai: Benchmark indices turned volatile in early trade Tuesday on escalating global trade concerns after US President Donald Trump announced new tariffs on an additional USD 200 billion worth of imports from China.
500820 BHRQY ASIANPAINT 500470 532121 HEROMOTOCO 500570 BHARTIARTL TATAMOTORS YESBANK IBN 532648 YYBKY 532401 VIJAYABANK 500182 532454 ICICIBANK TTST TATASTEEL TATLY 532174 HRTQY DENABANK TTM
Mumbai: Weak global markets amid the US-China trade concerns plunged the key Indian equity indices on Monday afternoon, with the S&P BSE Sensex losing around 400 points so far. The wider NSE Nifty50 also lost over 100 points during the intra-day trade. Among the sectors, heavy selling pressure was witnessed in banking, consumer durables and auto stocks. Globally, market sentiments were subdued on reports that the US might announce fresh tariffs on Chinese imports.
INDUSINDBK BHRQY 532454 500470 TTST 532187 TATASTEEL TATLY HDB 500180 HDFCBANK 500570 BHARTIARTL TATAMOTORS SBAZ TTM
Mumbai: The benchmark BSE Sensex sank over 350 points in early trade Monday after two sessions of gains as investors cashed profits in consumer durables, banking, oil & gas and PSU stocks, amid fresh weakness in the rupee and weak global cues.
YESBANK AXB INDUSINDBK 532648 YYBKY BHRQY 532215 AXBKY 532454 AXBA 532187 HDB AXISBANK 500180 HDFCBANK 500570 BHARTIARTL TATAMOTORS TTM
It’s a perfect photo finish for D-Street! The Nifty raced past 11,500 and ended the session above that mark. This is contrary to the negative moves that the market had in the first couple of days of the week.
SPARC 524715 BHRQY 532843 533278 AKLD CADILAHC CDLYY 532454 532872 532321 FORTIS SUNPHARMA 500477 BHARTIARTL AKLS CLNDY COALINDIA ASHOKLEY
London: India’s biggest mobile carrier Bharti Airtel Ltd has chosen UBS, JP Morgan and Citi to coordinate the London initial public offering of its Africa business, two sources familiar with the matter said.
532454 BHRQY BHARTIARTL
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...